Organization | Pharmicell Co., Ltd.

Pharmicell Co., Ltd. Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Seoul Korea, Republic of (1968)

Organization Overview

First Clinical Trial

2012

NCT01716481

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Pharmicell Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (2)

autologous dendritic cells (3 trials)

autologous mesenchymal stem cells (2 trials)

Drugs in Phase 2 Trials (1)

cellgram-ed (1 trial)

Drugs in Phase 1 Trials (4)

allogeneic adipose derived mesenchymal stem cell (1 trial)

autologous bone marrow derived mesenchymal cells (1 trial)

bone marrow derived mesenchymal stem cells (1 trial)

cellgram-dc-pc (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma, Ovarian Epithelial (Phase 1)

Erectile Dysfunction (Phase 2)

Fibrosis (Phase 1)

Ischemia (Phase 1)

Liver Cirrhosis (Phase 1)

Liver Cirrhosis, Alcoholic (Phase 1)

Ovarian Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 10
# of Trial APIs: 7